Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

AstraGenomics and Kactus Forge Gene Editing Partnership – Global Commercial Rights and Manufacturing Scale-Up for Nucleic Acid Therapeutics

Fineline Cube Mar 5, 2026
Company Deals

Rallybio to Acquire Candid Therapeutics in $700M+ Merger – Creates Leading Autoimmune T‑Cell Engager Company

Fineline Cube Mar 5, 2026
Company Deals

Edding Genor Expands ANGPTL3 siRNA Rights to Global – Restructures Napeptide Partnership

Fineline Cube Mar 4, 2026
Company Deals

Aidea Pharma Raises RMB 1.28B – $111M Allocated to Global HIV Integrase Inhibitor Development

Fineline Cube Mar 4, 2026
Company Deals

Star Sports Medicine Files Hong Kong IPO – Sports Medical Device Maker Targets Soft Tissue Injury Market

Fineline Cube Mar 4, 2026
Policy / Regulatory

China’s 2026 Government Work Report Unveils Healthcare Overhaul – VBP Optimization, TCM Innovation, and 300M Long‑Term Care Expansion

Fineline Cube Mar 5, 2026
Company Drug

HutchMed Initiates Phase I/IIa Trial for HMPL-A580 – Second Antibody-Targeted Triggered Conjugate Targets EGFR+ Solid Tumors

Fineline Cube Mar 5, 2026
Company Drug

AbbVie’s SKYRIZI Hits AFFIRM Study Endpoints in Crohn’s Disease – 55% Clinical Remission vs. 30% Placebo at Week 12

Fineline Cube Mar 5, 2026
Company Deals

Hong Kong Government Partners with AstraZeneca, Tigermed, and Simcere to Boost Innovation

Fineline Cube Oct 7, 2023

The government of the Hong Kong Special Administrative Region has entered into significant partnership agreements...

Company Drug

Everest Medicines and Calliditas Present New Data on Nefecon for IgA Nephropathy

Fineline Cube Oct 7, 2023

Everest Medicines (HKG: 1952), in partnership with Calliditas Therapeutics AB (Nasdaq: CALT), recently presented new...

Company Drug

Zhaoke Ophthalmology Completes Patient Enrollment for Phase III Trials of TAB014 and Epinastine

Fineline Cube Oct 7, 2023

Zhaoke Ophthalmology Ltd (HKG: 6622), a former subsidiary of Lee’s Pharmaceutical Holdings Ltd (HKG: 0950),...

Company Drug

Amicus Therapeutics Secures FDA Approval for Pombiliti and Opfolda Combination Therapy

Fineline Cube Oct 7, 2023

Amicus Therapeutics (NASDAQ: FOLD), headquartered in the United States, has announced that it has received...

Company Deals

Vela Diagnostics Partners with SRL Inc. to Expand Molecular Diagnostics in Japan

Fineline Cube Oct 7, 2023

Singapore-based Vela Diagnostics, a global leader in integrated molecular solutions for diagnosing infectious diseases and...

Company Drug

Transcenta Secures FDA Approval for Phase III Trial of Osemitamab

Fineline Cube Oct 7, 2023

China-based Transcenta Holding Ltd (HKG: 6628) has announced that it has received approval from the...

Policy / Regulatory

Shanghai Boosts Community Healthcare with Enhanced Reimbursement and Services

Fineline Cube Sep 28, 2023

Shanghai’s healthcare security administration has announced a comprehensive set of measures aimed at enhancing community...

Company Deals

Novo Nordisk and Evotec Launch LAB eN² to Accelerate Drug Discovery for Rare Diseases

Fineline Cube Sep 28, 2023

Global healthcare company Novo Nordisk (NYSE: NVO) and drug discovery alliance Evotec (NASDAQ: EVO) have...

Company Deals

Roche Secures Global Rights to Ionis Pharmaceuticals’ Alzheimer’s and Huntington’s Disease Candidates

Fineline Cube Sep 28, 2023

Swiss pharmaceutical giant Roche (SWX: ROG) has announced the acquisition of global rights to develop,...

Company Drug

Takeda Receives FDA Approval for Subcutaneous Entyvio as UC Maintenance Therapy

Fineline Cube Sep 28, 2023

The US Food and Drug Administration (FDA) has granted Japan’s Takeda Pharmaceuticals (TYO: 4502) regulatory...

Company Medical Device

Neusoft Medical’s NeuRT Aurora Receives NMPA Approval for Advanced Radiotherapy Platform

Fineline Cube Sep 28, 2023

Neusoft Medical Systems Co., Ltd, a leading player in the medical technology sector, has announced...

Company Medical Device

CStone Pharmaceuticals’ PDGFRA Mutation Detection Kit Receives NMPA Approval

Fineline Cube Sep 28, 2023

CStone Pharmaceuticals (HKG: 2616), a China-based biopharmaceutical company, has announced that it has received marketing...

Company Deals

RemeGen and Akeso Biopharma Initiate Phase II Study for Gastric Cancer Combo Therapy

Fineline Cube Sep 28, 2023

China-based RemeGen Ltd (HKG: 9995) is poised to conduct a Phase II clinical study in...

Company Drug

Eli Lilly’s Insulin Biosimilar YouBiAn Approved for Diabetes Treatment in China

Fineline Cube Sep 28, 2023

US pharmaceutical major Eli Lilly (NYSE: LLY) has announced that it has received market approval...

Company Drug

Everest Medicines’ Xerava Receives Marketing Approval from TFDA for cIAI Treatment

Fineline Cube Sep 28, 2023

Everest Medicines (HKG: 1952) has announced that it has received marketing approval for its antibiotic...

Company Medical Device

Sino Medical Sciences Receives Turkish Approval for HT Supreme Drug-Eluting Stent System

Fineline Cube Sep 28, 2023

Sino Medical Sciences Technology Inc., (SHA: 688108), a leading Chinese medical device company, has announced...

Company Drug

Konruns Pharmaceutical’s KC1036 Pediatric Indication Accepted for NMPA Review

Fineline Cube Sep 28, 2023

Beijing-based Konruns Pharmaceutical Co., Ltd (SHA: 603590) has announced that the National Medical Products Administration...

Company Drug

Elpiscience Biopharmaceuticals Initiates Phase I Trial for Anti-LILRB2 Antibody ES009

Fineline Cube Sep 28, 2023

Elpiscience Biopharmaceuticals, a China-based biopharmaceutical company, has announced that the first patient has been dosed...

Company Deals

Triastek Inc. Secures $20.5 Million in Pre-Series C Financing for 3D Printing Pipeline

Fineline Cube Sep 28, 2023

China-based Triastek Inc., a company at the forefront of pharmaceutical-focused 3D printing, has reportedly secured...

Company Drug

Tasly Pharmaceuticals Gets NMPA Approval for B1344 Clinical Study in NASH

Fineline Cube Sep 28, 2023

Tasly Pharmaceuticals (SHA: 600535), a China-based pharmaceutical company, has announced that it has received approval...

Posts pagination

1 … 430 431 432 … 631

Recent updates

  • HutchMed Initiates Phase I/IIa Trial for HMPL-A580 – Second Antibody-Targeted Triggered Conjugate Targets EGFR+ Solid Tumors
  • AbbVie’s SKYRIZI Hits AFFIRM Study Endpoints in Crohn’s Disease – 55% Clinical Remission vs. 30% Placebo at Week 12
  • China’s 2026 Government Work Report Unveils Healthcare Overhaul – VBP Optimization, TCM Innovation, and 300M Long‑Term Care Expansion
  • AstraGenomics and Kactus Forge Gene Editing Partnership – Global Commercial Rights and Manufacturing Scale-Up for Nucleic Acid Therapeutics
  • Ab&B Bio-Tech Wins FDA IND Approval for mRNA Mpox Vaccine – China’s First U.S.-Cleared Candidate Targets Immunocompromised Populations
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

HutchMed Initiates Phase I/IIa Trial for HMPL-A580 – Second Antibody-Targeted Triggered Conjugate Targets EGFR+ Solid Tumors

Company Drug

AbbVie’s SKYRIZI Hits AFFIRM Study Endpoints in Crohn’s Disease – 55% Clinical Remission vs. 30% Placebo at Week 12

Policy / Regulatory

China’s 2026 Government Work Report Unveils Healthcare Overhaul – VBP Optimization, TCM Innovation, and 300M Long‑Term Care Expansion

Company Deals

AstraGenomics and Kactus Forge Gene Editing Partnership – Global Commercial Rights and Manufacturing Scale-Up for Nucleic Acid Therapeutics

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.